NEXUS trial: a multicenter phase II clinical study evaluating the efficacy and safety of the perioperative use of encorafenib, binimetinib, and cetuximab in patients with previously untreated surgically resectable BRAF V600E mutant colorectal oligometastases

BACKGROUND: The optimal treatment strategy for resectable BRAF V600E mutant colorectal oligometastases (CRM) has not been established due to the rarity and rapid progression of the disease. Since the unresectable recurrence rate is high, development of novel perioperative therapies are warranted. On...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Shin, Bando, Hideaki, Taketomi, Akinobu, Takamoto, Takeshi, Shinozaki, Eiji, Shiozawa, Manabu, Hara, Hiroki, Yamazaki, Kentaro, Komori, Koji, Matsuhashi, Nobuhisa, Kato, Takeshi, Kagawa, Yoshinori, Yokota, Mitsuru, Oki, Eiji, Komine, Keigo, Takahashi, Shinichiro, Wakabayashi, Masashi, Yoshino, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440878/
https://www.ncbi.nlm.nih.gov/pubmed/37605122
http://dx.doi.org/10.1186/s12885-023-11311-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440878/
https://www.ncbi.nlm.nih.gov/pubmed/37605122
http://dx.doi.org/10.1186/s12885-023-11311-5

Ejemplares similares